Simplex Trading, LLC Scynexis Inc Transaction History

Simplex Trading, LLC

  • $195 Billion
  • Q3 2025

A detailed history of Simplex Trading, LLC transactions in Scynexis Inc stock. As of the latest transaction made, Simplex Trading, LLC holds 104 shares of SCYX stock, worth $61. This represents 0.0% of its overall portfolio holdings.

Number of Shares
104
Previous 1,967 94.71%
Holding current value
$61
Previous $1,000 100.0%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Nov 12, 2025
SELL
$0.68 - $1.19 $1,266 - $2,216
-1,863 Reduced 94.71%
104 $0
Q2 2025

Aug 05, 2025
BUY
$0.67 - $1.07 $1,317 - $2,104
1,967 New
1,967 $1,000
Q4 2024

Feb 11, 2025
BUY
$1.0 - $1.53 $350 - $535
350 New
350 $0
Q1 2024

Apr 25, 2024
SELL
$1.39 - $2.21 $646 - $1,027
-465 Reduced 4.41%
10,086 $14,000
Q4 2023

Feb 02, 2024
BUY
$1.56 - $2.24 $1,935 - $2,779
1,241 Added 13.33%
10,551 $23,000
Q3 2023

Nov 01, 2023
BUY
$1.93 - $3.64 $17,968 - $33,888
9,310 New
9,310 $21,000
Q1 2023

Apr 27, 2023
BUY
$1.15 - $3.0 $81,489 - $212,580
70,860 New
70,860 $212,000
Q2 2022

Aug 03, 2022
SELL
$1.77 - $3.87 $2,401 - $5,251
-1,357 Closed
0 $0
Q1 2022

May 02, 2022
SELL
$3.56 - $6.66 $4,599 - $8,604
-1,292 Reduced 48.77%
1,357 $5,000
Q4 2021

Feb 23, 2022
BUY
$4.94 - $7.69 $13,086 - $20,370
2,649 New
2,649 $16,000
Q2 2021

Aug 12, 2021
SELL
$6.5 - $9.97 $15,736 - $24,137
-2,421 Closed
0 $0
Q1 2021

Apr 26, 2021
BUY
$6.93 - $9.63 $13,312 - $18,499
1,921 Added 384.2%
2,421 $19,000
Q4 2020

Feb 02, 2021
BUY
$4.28 - $7.87 $2,140 - $3,935
500 New
500 $3,000

Others Institutions Holding SCYX

# of Institutions
47
Shares Held
12.5M
Call Options Held
0
Put Options Held
0
View Full List

About SCYNEXIS INC

SCYX Quotes by TradingView
  • Ticker SCYX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 32,651,800
  • Market Cap $19.3M
  • Description
  • SCYNEXIS, Inc., a biotechnology company, develops products for the treatment fungal infections in the United States. It offers BREXAFEMME (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC). The company is developing its lead product candidate, Ibrexafungerp, as a novel oral and intravenous drug for the treatment of vario...
More about SCYX
Track This Portfolio

Track Simplex Trading, LLC Portfolio

Follow Simplex Trading, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Simplex Trading, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Simplex Trading, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email